Eligibility

Paediatric patients

If the patient is under the age of 16 at the time of consent, and starting any biologic or small molecule treatment for psoriasis, the patient will be eligible for BADBIR as long as they meet the rest of the eligibility criteria from that cohort.

Any queries, please contact us at badbir@manchester.ac.uk or on 0161 306 1896.

All patients

  • Must have a diagnosis of psoriasis
  • Perform written informed consent
  • Therapy must be ongoing at the time of consent
  • Must have started or switched therapy within six months of the date of consent
  • Must have a PASI and DLQI within 6 months prior to patient starting therapy
  • Patients should be added to the BADBIR database within 6 months of consenting

Biologic cohort

  • There is no minimum PASI or DLQI score required, but scores need to be taken within six months prior to the patient commencing therapy, so we have a baseline disease severity measure.
  • The biologic therapies we recruit for are:
Adalimumab biosimilars
Amgevita (recruitment ends 1st October)
Imraldi
Etanercept biosimilars
Benepali
Erelzi
All other biologic therapies
Cimzia (certolizumab pegol)
Cosentyx (secukinumab)
Ilumetri (tildrakizumab)
Kyntheum (brodalumab)
Skyrizi (risankizumab) - NEW
Taltz (ixekizumab)
Tremfya (guselkumab)

Conventional cohort

  • The patient must be naïve to biologic therapy.
  • The patient's PASI at the time the drug is started must be greater than or equal to 10 (10 or more), and the DLQI greater than 10 (11 or more).
  • There is no minimum PASI or DLQI score if the patient is switching between conventional therapies (less than a 3 month gap between stopping one conventional and starting another), or if the patient has an ongoing conventional treatment and is being registered on a new conventional alongside this. Although the dermatologist must deem the patient to have a history of moderate to severe psoriasis, with a score provided prior to the new conventional the patient has commenced.
  • The conventional therapies we recruit for are:
Conventional therapies
Acitretin
Ciclosporin
Fumaric acid esters
Hydroxycarbamide
Methotrexate
Systemic oral PUVA - please note we don't recruit for bath PUVA

Non-Biologic Small Molecule cohort

  • The patient must be naïve to biologic therapy.
  • There is no minimum PASI or DLQI score required, but scores need to be taken within six months prior to the patient commencing their treatment, so we have a baseline disease severity measure.
  • The non-biologic small molecule therapies we recruit for are:
Small molecule therapies
Skilarence (dimethyl fumarate)